EcoR1 Capital PHAT Position
Exited3-Fund ConvergenceEcoR1 Capital exited their position in Phathom Pharmaceuticals Inc. (PHAT) in Q1 2024, after holding the stock for 4 quarters.
The position was first reported in Q2 2023 and has been tracked across 4 quarterly 13F filings.
PHAT is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 22.9% of float with 12.2 days to cover, indicating significant bearish positioning against the stock.
About Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Full company profile →Short Interest
22.9%
12.2 days to cover
EcoR1 Capital PHAT Position History
Frequently Asked Questions
Does EcoR1 Capital own PHAT?
No. EcoR1 Capital exited their position in Phathom Pharmaceuticals Inc. (PHAT) in Q1 2024. They previously held the stock for 4 quarters.
How many hedge funds own PHAT?
3 specialist biotech hedge funds currently hold PHAT, including OrbiMed Advisors, Deerfield Management, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy PHAT?
EcoR1 Capital's position in PHAT was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's PHAT position increasing or decreasing?
EcoR1 Capital completely exited their PHAT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PHATCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →